The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $10.24

Today's change-0.56 -5.19%
Updated June 29 4:00 PM EDT. Delayed by at least 15 minutes.
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $10.24

Today's change-0.56 -5.19%
Updated June 29 4:00 PM EDT. Delayed by at least 15 minutes.

Infinity Pharmaceuticals Inc down (U.S.)$0.56

Infinity Pharmaceuticals Inc closed sharply lower Monday, dropping (U.S.)$0.56 or 5.19% to (U.S.)$10.24. Over the last five days, shares have lost 12.18% and are down 39.37% for the last year to date. This security has underperformed the S&P 500 by 23.34% during the last year.

Key company metrics

  • Open(U.S.) $10.79
  • Previous close(U.S.) $10.80
  • High(U.S.) $10.80
  • Low(U.S.) $10.23
  • Bid / Ask-- / --
  • YTD % change-39.37%
  • Volume521,408
  • Average volume (10-day)547,995
  • Average volume (1-month)709,169
  • Average volume (3-month)680,794
  • 52-week range(U.S.) $8.80 to (U.S.) $18.25
  • Beta1.25
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.39
Updated June 29 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-40.42%

Although this company's net profit margin is negative, it is above the industry average and implies that Infinity Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX2.15%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue441610
Total other revenue--------
Total revenue441610
Gross profit--------
Total cost of revenue--------
Total operating expense97435335
Selling / general / administrative9787
Research & development88364528
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-93-39108-35
Interest income (expense), net non-operating-1-1-5-3
Gain (loss) on sale of assets--------
Other--------
Income before tax-93-40103-38
Income after tax-93-40103-38
Income tax, total--0--0
Net income-93-40103-38
Total adjustments to net income-----2--
Net income before extra. items-93-40103-38
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-93-40101-38
Inc. avail. to common incl. extra. items-93-40101-38
Diluted net income-93-40101-38
Dilution adjustment------0
Diluted weighted average shares49495049
Diluted EPS excluding extraordinary itemsvalue per share-1.91-0.832.03-0.78
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.91-0.832.03-0.78